Changes are being made to the US vaccine landscape, with a restructured CDC advisory committee. The impact of these changes is uncertain, with some outlets reporting potential cuts to vaccine development and grants, while others discuss concerns over the influence of industry on federal vaccine advisers. The developments are part of a broader shift in the country's approach to public health, with various factors and stakeholders involved.